Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Lecia V. Sequist(Harvard University), D. Ross Camidge(University of Colorado Denver), Mitch Raponi(Clovis Oncology (United States)), Jeffrey D. Isaacson, Jean‐Charles Soria(Inserm), Chris Karlovich(Clovis Oncology (United States)), Shirish M. Gadgeel(Chinese University of Hong Kong), Cathy Galasso(Wayne State University), Joel W. Neal(Stanford Medicine), Robert C. Doebele(Aurora University), Heather A. Wakelee(Palo Alto Institute), Jonathan W. Goldman(University of California, Los Angeles), Sarah Jaw‐Tsai(Clovis Oncology (United States)), Melody Mendenhall(University of California, Los Angeles), Geoffrey R. Oxnard(Foundation Medicine (United States)), Benjamin Solomon(Peter MacCallum Cancer Centre), Dara L. Aisner(University of Colorado System), Rafał Dziadziuszko(Gdańsk Medical University), Edward B. Garon(University of California, Los Angeles), Rebecca S. Heist(Massachusetts General Hospital), Andrew R. Allen(Vanderbilt University), Zofia Piotrowska(Global Cancer Institute), Darrin Despain(Clovis Oncology (United States)), Andréa Varga(Institut Gustave Roussy), Antoinette J. Wozniak(Wayne State University), Jennifer Logan(Massachusetts General Hospital), Lindsey Rolfe, Vassiliki A. Papadimitrakopoulou(Pfizer (United States)), Suzanne Nichols(University of California, Los Angeles), Shannon Matheny(Clovis Oncology (United States))
New England Journal of Medicine
April 29, 2015
Cited by 664


Related Papers